Osimertinib Plus Chemo Improves CNS PFS in EGFR+ Advanced NSCLC With Baseline Brain Metastases
October 21st 2023Osimertinib plus chemotherapy reduced the risk of central nervous system disease progression or death vs osimertinib alone in patients with locally advanced or metastatic EGFR-positive non–small cell lung cancer who had brain metastases at baseline, according to data from the phase 3 FLAURA2 trial.
Selpercatinib Significantly Improves PFS, Responses in Advanced RET+ Medullary Thyroid Cancer
Selpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients with advanced, multikinase inhibitor–naïve, RET-mutant medullary thyroid cancer, according to interim findings from the phase 3 LIBRETTO-531 trial.
Amivantamab Plus Chemotherapy Nearly Doubles PFS in EGFR Exon 20–Mutant NSCLC
October 21st 2023The combination of amivantamab-vmjw (Rybrevant) and chemotherapy produced a median progression-free survival of 11.4 months vs 6.7 months with chemotherapy alone in patients with advanced, EGFR exon 20 insertion–positive non–small cell lung cancer.
Maintenance Durvalumab Plus Olaparib Improves PFS in Advanced or Recurrent Endometrial Cancer
October 21st 2023The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.
Perioperative Nivolumab Significantly Improves EFS in Previously Untreated Resectable NSCLC
October 21st 2023Neoadjuvant treatment with nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab resulted in a statistically significant improvement in event-free survival vs placebo plus chemotherapy, in patients with previously untreated resectable stage II to IIIB non-small cell lung cancer, according to data from the phase 3 CheckMate 77T trial.
Selpercatinib Significantly Improves PFS Vs Chemo With or Without Pembrolizumab in RET+ NSCLC
Selpercatinib (Retevmo) showcased superior efficacy, with improved progression-free survival, vs chemotherapy with or without pembrolizumab in the first-line treatment of patients with RET fusion–positive non–small cell lung cancer.
Trastuzumab Deruxtecan Sustains Survival Benefits in HER2-Low Metastatic Breast Cancer
October 21st 2023Treatment with fam-trastuzumab deruxtecan-nxki led to sustained improvements in overall survival and progression-free survival vs physician’s choice of treatment in patients with previously treated HER2-low metastatic breast cancer, irrespective of hormone receptor status.
Belzutifan Plus Cabozantinib Delivers Durable Responses in ccRCC
October 21st 2023Belzultifan in combination with cabozantinib generated durable responses independent of International Metastatic RCC Database Consortium risk category in patients with treatment-naïve clear cell renal cell carcinoma or those who had received prior immunotherapy.
Second-Line Sacituzumab Govitecan Elicits Responses, Provides Disease Control in ES-SCLC
Second-line treatment with sacituzumab govitecan-hziy led to responses in patients with extensive-stage small cell lung cancer, according to results from the phase 2 TROPiCS-03 trial.
Sacituzumab Govitecan Demonstrates Modest Activity in Pretreated HNSCC
October 21st 2023Sacituzumab govitecan-hziy led to modest but durable antitumor activity with predominant gastrointestinal toxicities in patients with metastatic or locally recurrent head and neck squamous cell carcinoma who received between 1 and 3 prior lines of therapy.
Atezolizumab Plus Chemotherapy Fails to Provide Clinical Benefit in Recurrent Ovarian Cancer
Patients with recurrent ovarian cancer did not experience a statistically significant improvement in clinical outcomes such as progression-free survival and objective response rate with the addition of atezolizumab to chemotherapy and niraparib maintenance therapy.
Neoadjuvant Pembrolizumab Plus Chemotherapy Boosts pCR in ER+/HER2– Breast Cancer
October 20th 2023Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy generated a statistically significant increase in pathologic complete response vs neoadjuvant placebo plus chemotherapy followed by adjuvant pembrolizumab and endocrine therapy in patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.
Dostarlimab Plus Chemo Continues to Demonstrate Strong Clinical Efficacy in Advanced NSCLC
Dostarlimab plus chemotherapy elicited a higher objective response rate and showcased a numerical improvement in overall survival compared with pembrolizumab and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.
Lutetium Lu 177 Vipivotide Tetraxetan Plus Enzalutamide Elicits PSA-PFS Improvement in mCRPC
October 20th 2023Treatment with the combination of lutetium Lu 177 vipivotide tetraxetan and enzalutamide led to an improvement in prostate-specific antigen progression-free survival vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer.
Pembrolizumab Plus Neoadjuvant Chemotherapy Produces Long-Term Survival Benefits in High-Risk TNBC
October 20th 2023Treatment with neoadjuvant pembrolizumab in combination with platinum-containing chemotherapy and followed by adjuvant pembrolizumab improved event-free survival compared with neoadjuvant chemotherapy alone in patients with high-risk triple-negative breast cancer.
Frontline Pembrolizumab Plus Trastuzumab/Chemotherapy Improves PFS in HER2+ Gastric/GEJ Cancer
The addition of pembrolizumab to combination of trastuzumab and chemotherapy led to an improvement in progression-free survival vs placebo plus trastuzumab and chemotherapy in the first-line treatment of patients with metastatic HER2-positive gastric or gastroesophageal junction cancer, particularly in those whose tumors had a PD-L1 combined positive score.
Pembrolizumab Plus Adagrasib Demonstrates Preliminary Efficacy in KRAS G12C–Mutated NSCLC
October 20th 2023Concurrent adagrasib and pembrolizumab generated early signals of efficacy in patients with treatment-naïve, advanced non–small cell lung cancer harboring KRAS G12C mutations, particularly in those who had a PD-L1 tumor proportion score of at least 50%.
Durvalumab Plus Chemotherapy Elicits pCR Improvement in Resectable Gastric/GEJ Cancer
The addition of durvalumab to 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel produced statistically significant and clinically meaningful improvements in pathological complete response rates vs placebo plus FLOT in patients with resectable gastric cancer or gastroesophageal junction cancer.